Gruber Günther, Menzi Samuel, Forster Andrea, Berclaz Gilles, Altermatt Hans-Jörg, Greiner Richard H
Department of Radiation Oncology, Inselspital, University of Berne, Switzerland.
Strahlenther Onkol. 2005 Sep;181(9):574-9. doi: 10.1007/s00066-005-1367-x.
Extracapsular spread (ECS) is frequent, but the specific sites of relapse are seldom given in the literature. In this study it was evaluated, if ECS might be an indicator for axillary irradiation.
After a retrospective review of pathology reports, the information about ECS was available in 254 lymph node-positive patients: ECS was absent in 34% (ECS-negative; n = 87) and present in 66% (ECS-positive; n = 167). All patients were irradiated locally, 78 patients got periclavicular and 74 axillary irradiation (median total dose: 50.4 Gy). 240/254 patients (94.5%) received systemic treatment/s. Mean follow-up was 46 months.
The regional relapse rate was 4.6% without ECS versus 9.6% with ECS. The 5-year axillary relapse-free survival was 100% in ECS-negative and 90% in ECS-positive patients (p = 0.01), whereas corresponding values for periclavicular relapse-free survival (with ECS: 91% +/- 4%; without ECS: 94% +/- 3%; p = 0.77) and local relapse-free survival (with ECS: 86% +/- 4%; without ECS: 91% +/- 3%; p = 0.69) were not significantly different. chi(2)-tests revealed a high correlation of ECS with T-stage, number of positive lymph nodes and progesterone receptor status, comparisons with estrogen receptor, grade, or age were not significant. In multivariate analysis number of positive lymph nodes was solely significant for regional failure. Dividing the patients into those with one to three and those with four or more positive lymph nodes, ECS lost its significance for axillary failure.
ECS was accompanied by an enhanced axillary failure rate in univariate analysis, which was no longer true after adjusting for the number of positive lymph nodes.
囊外扩散(ECS)很常见,但文献中很少提及复发的具体部位。在本研究中,评估ECS是否可能是腋窝放疗的一个指标。
回顾病理报告后,254例淋巴结阳性患者中有关于ECS的信息:34%(ECS阴性;n = 87)无ECS,66%(ECS阳性;n = 167)有ECS。所有患者均接受局部放疗,78例接受锁骨上放疗,74例接受腋窝放疗(中位总剂量:50.4 Gy)。240/254例患者(94.5%)接受了全身治疗。平均随访时间为46个月。
无ECS时区域复发率为4.6%,有ECS时为9.6%。ECS阴性患者的5年腋窝无复发生存率为100%,ECS阳性患者为90%(p = 0.01),而锁骨上无复发生存率(有ECS:91%±4%;无ECS:94%±3%;p = 0.77)和局部无复发生存率(有ECS:86%±4%;无ECS:91%±3%;p = 0.69)的相应值无显著差异。卡方检验显示ECS与T分期、阳性淋巴结数量和孕激素受体状态高度相关,与雌激素受体、分级或年龄的比较无显著差异。多因素分析中,阳性淋巴结数量对区域失败单独具有显著性。将患者分为1至3个阳性淋巴结和4个或更多阳性淋巴结两组,ECS对腋窝失败不再具有显著性。
单因素分析中,ECS伴有腋窝失败率增加,但在调整阳性淋巴结数量后情况不再如此。